Galaxy Watch Data to Be Used in New Drug Development... Samsung Electronics Partners with German Alchadis

Developing Methods to Utilize Wearable Data as Clinical Indicators

Building a 'Connected Care' Ecosystem to Benefit Patients

Samsung Electronics will begin actively utilizing biometric data collected through the Galaxy Watch in clinical trials for new drug development.

Samsung Electronics (left) and Alchedis logos. Courtesy of Samsung Electronics

On the 24th, Samsung Electronics announced that it has entered into a partnership with Alchadis, a data-driven digital clinical trial specialist, expanding the application of wearable technology from everyday health management to the field of medical research.

Founded in 1992, Alchadis is a German company specializing in digital clinical trials, with over 30 years of experience conducting clinical studies in oncology, cardiology, neurology, and other areas. Currently a subsidiary of the global healthcare artificial intelligence (AI) company Huma Group, Alchadis is leading the digital transformation of clinical research.

The two companies will jointly develop methods to convert biometric data collected in real-world settings via Galaxy Watch sensors into clinical indicators. These indicators will be used to evaluate the efficacy and safety of new drugs. In addition, the two companies will collaborate extensively throughout the entire clinical research process, including data collection, participant monitoring, clinical trial operations, and regulatory compliance.

Choi Jongmin, Executive Vice President of the Health Development Group at Samsung Electronics MX Division, stated, "Clinical research is advancing toward a deeper understanding of human health through the collaboration of partners with technological and scientific expertise. Through this partnership, we aim to ensure that everyday data leads to innovation in new drug research and benefits for patients."

Hanno Hertlein, CEO of Alchadis, commented, "The future of clinical research depends on how much meaningful health data can be captured in everyday life, beyond traditional clinical settings. By combining the strengths and scalable infrastructure of both companies, we will accelerate research and achieve more patient-centric healthcare innovation."

Meanwhile, Samsung Electronics is building a "connected care" ecosystem that links health data from wearable devices with actual medical services. This reflects the latest trends in healthcare, shifting from hospital-based care to daily life, and from post-treatment to preventive care.

As a key strategy, last year Samsung Electronics acquired JELLS, a platform company that connects digital healthcare solutions with more than 500 major hospitals in the United States. Moving forward, the company plans to link health data from Galaxy devices to hospital electronic health record (EHR) systems to support personalized, prevention-focused medical services.

This content was produced with the assistance of AI translation services.